Skip to main content
SpringerLink
Log in

Medición y evaluación de los resultados en salud en las evaluaciones económicas

  • Chapter
  • First Online:
Evaluación económica de medicamentos y tecnologías sanitarias:

  • 821 Accesses

Resumen

En cualquier evaluación económica, la correcta valoración de los resultados en salud obtenidos tras la administración de las opciones terapéuticas en estudio es uno de los pilares básicos (junto con los costes generados) para poder obtener conclusiones que sean válidas, creíbles y de relevancia para los decisores. De hecho, no incorporar los resultados en salud más apropiados (que estén menos sesgados y que sean de la mayor calidad) es una de las críticas que con más frecuencia se realiza a la hora de valorar evaluaciones económicas ya efectuadas (1,2).

Si quieres ser sabio, aprende a preguntar con respeto, a escuchar con atención, a responder serenamente y a callar cuando no tengas nada que decir.

Johann Kaspar

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Demicheli V, Jefferson T, Vale L. Effectiveness estimates in economic evaluation. In: Donaldson C, Mugford M, Vale L, eds. Evidence-based Health Economics. London: BMJ Books, 2002: 89–98.

    Google Scholar 

  2. Hanratty B, Craig D, Nixon J, Rice S, Christie J, Drummond M. Are the best available clinical effectiveness data used in economic evaluations of drug therapies? J Health Serv Res Policy 2007; 12: 138–141.

    Google Scholar 

  3. Johannesson M, Jönsson B, Karlsson G. Outcome measurement in economic evaluation. Health Econ 1996; 5: 279–296.

    Google Scholar 

  4. Revicki DA, Frank KL. Pharmacoeconomic evaluation in the real world: effectiveness versus efficacy studies. Pharmacoeconomics 1999; 15: 423–434.

    Google Scholar 

  5. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989; 5: 559–575.

    Google Scholar 

  6. Schechtman E. Odds ratio, relative risk, absolute risk reduction, and the number needed to treatwhich of these should we use? Value Health 2002; 5: 431–436.

    Google Scholar 

  7. Abraira V. Medidas del efecto de un tratamiento (I): reducción absoluta del riesgo, reducción relativa del riesgo y riesgo relativo. Semergen 2000; 26: 535–536.

    Google Scholar 

  8. Gabriel R. ¿Nos cuentan los ensayos clínicos toda la verdad? Riesgos relativos y absolutos y su influencia en las decisiones terapéuticas de los cardiólogos. Rev Esp Cardiol 2002; 55: 1018–1020.

    Google Scholar 

  9. Abraira V. Medidas del efecto de un tratamiento (II): odds ratio y número necesario para tratar. Semergen 2000; 27: 418–420.

    Google Scholar 

  10. Sackett DL, Richarson WS, Rosenberg W, Hynes RB. Evidence-based medicine: how to practice and teach EBM. London: Churchill-Livingstone, 1997.

    Google Scholar 

  11. Casado A, Prieto L, Alonso J. El tamaño del efecto de la diferencia entre las medidas: ¿estadísticamente significativo o clínicamente relevante? Med Clin (Barc) 1999; 112: 584–588.

    Google Scholar 

  12. Kraemer H Ch, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 2006; 59: 990–996.

    Google Scholar 

  13. Bonneux L. How to measure the burden of mortality? J Epidemiol Community Health 2002; 56: 128–131.

    Google Scholar 

  14. Garcia LA, Nolasco A, Bolumar F, Alvarez-Dardet C. Los años potenciales de vida perdidos: una forma de evaluar las muertes prematuras. Med Clin (Barc) 1986; 87: 55–57.

    Google Scholar 

  15. Guy GP, Ekwueme DU. Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer. Pharmacoeconomics 2011: 29: 863–874.

    Google Scholar 

  16. Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP. Years of life lost (YLL) from cancer is an important measure of population burden-and should be considered when allocating research funds. Br J Cancer 2005; 92: 241–245.

    Google Scholar 

  17. Manuel DG, Schultz SE. Health-related quality of life and health-adjusted life expectancy of people with diabetes in Ontario, Canada, 1996–1997. Diabetes Care 2004; 27: 407–414.

    Google Scholar 

  18. Berthelot JM. Health-adjusted life expectancy. In:"Determining Health Expectancies". Ed: Robine JM, Jagger C, Mathers CD, Crimmins EM, Suzman RM. John Wiley & Sons, Ltd., 2003.

    Google Scholar 

  19. Robine JM. Disability-free life expectancy. General indicators of the health of the population. Scientific report. Quebec: conseil des affaires socials et de la famille. 1986.

    Google Scholar 

  20. Gold MR, Stevenson D, Fryback DG. HALYs and QALYs and DALYs, oh my: similarities and differences in summary measures of population health. Annu Rev Public Health 2002; 23: 115–134.

    Google Scholar 

  21. Mont D. Measuring health and disability. Lancet 2007; 369: 1658–1663.

    Google Scholar 

  22. Anand S, Hanson K. Disability-adjusted life years: A critical review. J Health Econ 1997; 16: 685–702.

    Google Scholar 

  23. Fox-Rushby JA, Hanson K. Calculating and presenting disability adjusted life years (DALYs) in costeffectiveness analysis. Health Policy Planning 2001; 16: 326–331.

    Google Scholar 

  24. Murray CJL, Acharya AK. Understanding DALYs. J Health Econ 1997; 16: 703–730.

    Google Scholar 

  25. Hampus Lyttkens C. Time to disable DALYs? On the use of disability-adjusted life years in health policy. Eur J Health Econ 2003; 4: 195–202.

    Google Scholar 

  26. Lazaro A. Theoretical arguments for the discounting of health consequences. Where do we go from here? Pharmacoeconomics 2002; 20: 943–961.

    Google Scholar 

  27. Severens JL, Milne RJ. Discounting health outcomes in economic evaluation: the ongoing debate. Value Health 2004; 7: 397–401.

    Google Scholar 

  28. Klimlt CR. The conduct and principles of randomized clinical trials. Control Clin Trials 1981; 1: 283–293.

    Google Scholar 

  29. Moses LE. Measuring effects without randomized trials? Options, problems and challenges. Med Care 1995; 33: AS8-AS14.

    Google Scholar 

  30. Egger M, Davey Smith G, Attman DG. Systematic reviews in health care: meta-analysis in context. London: BMJ Books, 2000.

    Google Scholar 

  31. Song F, Altman DG, Glenny MA. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003; 326: 472–476.

    Google Scholar 

  32. Brennan A, Akehurst R. Modelling in health economic evaluation. Pharmacoeconomics 2000; 17: 445–459.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Freelance, C/ Arturo Soria 148, 1°-1°, Madrid, 28043, Madrid, Spain

    Javier Soto Álvarez

Authors
  1. Javier Soto Álvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Javier Soto Álvarez .

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Healthcare Iberica, S.L.

About this chapter

Cite this chapter

Soto Álvarez, J. (2012). Medición y evaluación de los resultados en salud en las evaluaciones económicas. In: Evaluación económica de medicamentos y tecnologías sanitarias:. Springer Healthcare, Madrid. https://doi.org/10.1007/978-84-940346-6-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-84-940346-6-4_4

  • Published:

  • Publisher Name: Springer Healthcare, Madrid

  • Print ISBN: 978-84-940346-1-9

  • Online ISBN: 978-84-940346-6-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation